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The idea of using MRI to assess renal function dates back to the early 1980’s, when Runge et al 
demonstrated that serial MRI after contrast agent injection revealed temporal patterns that were 
able to diagnose acute changes in renal function (1). In the same period, Pettigrew et al 
demonstrated that fast imaging sequences could isolate renal perfusion (2), and concluded that “in 
the future, MR imaging […] may simultaneously provide good morphological detail and the type of 
physiologic information currently offered noninvasively by nuclear medicine techniques”. Ever since, 
functional renal MRI has been an active field of research within the MRI community. Commonly 
cited methods include diffusion-weighted imaging (3), diffusion-tensor imaging (4), blood-
oxygenation level dependent MRI (5) and arterial spin labelling (6), but many others have shown a 
relevant signal in the kidney: phase-contrast, T1-mapping, T2-mapping, Sodium, magnetisation 
transfer, chemical exchange saturation transfer, spectroscopy, rotating frame relaxation, 
elastography, volumetry, quantitative susceptibility mapping and hyperpolarised MRI. 
For 30 years these ideas were largely confined to the MR physics and radiology community, but the 
past few years have seen a rapidly increasing interest by nephrologists. To a large extent this is 
driven by the ever growing burden of chronic kidney disease (CKD) and the well-recognised need for 
“novel prognostic biomarkers that help to predict future risk and understand the underlying 
molecular mechanisms” (7). One possible avenue lies in the identification of novel biomarkers in 
blood or urine, but these have so far failed to produce a clear solution (8). It is increasingly 
recognised that MRI biomarkers may be part of the solution due to their ability to probe different 
pathophysiological hallmarks of CKD progression (9). Despite known limitations in terms of biological 
specificity, it appears plausible that a direct observation of parenchymal changes in-situ can pick up 
disease progression well before it manifests itself downstream in blood or urine.  
These converging interests of MR physicists, radiologists, nephrologists, drug developers, transplant 
surgeons, physiologists and pathologists have given rise to a dynamic and multi-disciplinary 
community of researchers with a common interest in renal MRI biomarkers. In Europe an 
international research network was founded in 2017 (www.renalmri.org) and only recently, in 
october 2019, a third international meeting on renal MRI was held attracting over 200 scientists 
from across these disciplines (10). As a result of this broadening interest MRI biomarkers are also 
increasingly visible in the nephrology literature (11), with one recent study hinting at a potential role 
in the long-standing problem of predicting disease progression (12).  
This special issue on MRI biomarkers of renal disease is intended to offer a cross-section of the 
ongoing developments in this area, and to encourage a more coordinated approach to MRI 
biomarker development in order to generate the evidence levels required by regulators (13).  
The four review papers in this issue cover ongoing areas of research including relatively well-
established methods (Caroli et al) and entirely novel contrast mechanisms (Laustsen et al), image 
processing (Zoellner et al) and clinical applications (Schutter et al). The original work in this issue is 
representative of the wider field and includes: the application of MRI to improve patient 
management (Serai et al) and our understanding of disease progression (Van Raalte et al); studies on 
sequence optimisation (Harteveldt et al, Miyazaki et al) and image processing methods (Rankin et al, 
Li et al) that may inform future technical recommendations; and technical developments that can 
open up new avenues of translational research (Boehmert et al).  
This special issue places a particular emphasis on research coordination, and presents a rigorous 
process developed by the community to generate expert consensus on technical aspects 
(Mendichovszky et al). Four papers present the results of applying this process to the most common 
contrast mechanisms and have jointly generated over 160 consensus statements (Nery et al, Dekkers 
et al, Ljimani et al, Bane et al). Apart from identifying areas where consensus already exists, this 
process has also served to identify research priorities by highlighting areas where experts are 
currently unable to agree on a recommendation. Our hope is that this mechanism will ultimately 
cause an alignment of the methods for measuring renal MRI biomarkers and create the necessary 
conditions for international harmonization. This in turn will allow clinical trials to be scaled up to the 
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